The NCI Community Oncology Research Program (NCORP) is a national network of cancer care investigators, providers, academia, and other organizations that care for diverse populations in health systems.
The DCP Community Oncology and Prevention Trials Research Group administers this program.
On This Page
- All Headings will automatically be pulled in to this list.
- Do not edit the content on this template.
About NCORP
The program brings cancer clinical trials and control and delivery studies to individuals in their own communities, thereby generating a broadly applicable evidence base that contributes to improved patient outcomes and a reduction in cancer disparities.
Grantee Details
No matching Grants were found.
Clinical Trials
| Title Sort descending | Intervention | Sponsor | Status |
|---|---|---|---|
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | Megestrol Acetate, Olanzapine, Questionnaire Administration | Alliance for Clinical Trials in Oncology | Recruiting |
| Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy | Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Ondansetron Hydrochloride, Palonosetron Hydrochloride, Placebo | Alliance for Clinical Trials in Oncology | Completed |
| Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors | Laboratory Biomarker Analysis, Omega-3 Fatty Acid, Placebo, Questionnaire Administration | Gary Morrow | Completed |
| Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer | Fulvestrant, Letrozole, Palbociclib, Quality-of-Life Assessment, Questionnaire Administration | Alliance for Clinical Trials in Oncology | Active, not recruiting |
| Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil | Donepezil 5 mg, Placebo | Wake Forest University Health Sciences | Completed |
| Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer | Endocrine therapy interruption | ETOP IBCSG Partners Foundation | Active, not recruiting |
| Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT) | Atorvastatin, Placebo | Wake Forest University Health Sciences | Completed |
| Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors | Entecavir, Tenofovir Disoproxil Fumarate, Best Practice, Tenofovir Alafenamide | SWOG Cancer Research Network | Active, not recruiting |
| Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer | Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration | Gary Morrow | Completed |
| Radiation Therapy in Treating Patients With Prostate Cancer | 36.25 Gy IMRT, 51.6 Gy IMRT | Radiation Therapy Oncology Group | Completed |